Evidence map›Paper›PMID 42871591›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Assessment of the Effects of Corporate Governance on the Competitiveness of Pharmaceutical Companies Through Improved Total Factor Productivity.

Mohammad Hossein Motevalli, Farzad Peiravian, Mohammad Peikanpour, Mohammad Moien Mansouri, Seyyed Ahmad Askari

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad Hossein MotevalliDepartment of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0002-1208-5692
Farzad PeiravianDepartment of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0002-2841-0808
Mohammad PeikanpourDepartment of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0002-7892-2588
Mohammad Moien MansouriCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy Tehran Iran.ORCID https://orcid.org/0009-0008-6285-6644
Seyyed Ahmad AskariDepartment of Traditional Pharmacy, Traditional Medicine and Materia Medica Research Center, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0001-7553-1912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Corporate governance, productivity, and competitiveness are widely recognized as key determinants of firm performance and long-term sustainability. Although each construct has been extensively studied individually, their interrelationships, particularly within the pharmaceutical industry of developing economies, remain insufficiently understood. This gap is especially relevant given the strategic and economic importance of the pharmaceutical sector. Objectives: This study aimed to assess the relationships among corporate governance, competitiveness, and productivity in Iranian pharmaceutical companies and to develop a model that better explains the interactions among these determinants. Methods: This cross-sectional study was conducted in three phases among Iranian pharmaceutical manufacturing companies. First, context-specific, validated questionnaires were developed to assess corporate governance, productivity, and competitiveness. Second, these instruments were administered to senior executives (Chief Executive Officers [CEOs], board members, Chief Financial Officers [CFOs], and Chief Commercial Officers [CCOs]) at 44 randomly selected companies. Finally, statistical analyses, including Pearson and partial correlations, independent t-tests, and bootstrapped mediation analysis, were performed to evaluate the relationships among the study variables. Results: A total of 151 completed questionnaires were analyzed (response rate: 85.8%). Productivity showed a strong positive correlation with competitiveness (r = 0.780, P < 0.001) and a moderate positive correlation with corporate governance (r = 0.419, P = 0.005). By contrast, no significant direct correlation was observed between corporate governance and competitiveness. Mediation analysis indicated that productivity mediated the relationship between corporate governance and competitiveness, indicating a substantial indirect effect. In addition, companies producing biological medicines had significantly higher productivity and competitiveness scores. Conclusions: The findings suggest a partially interdependent model in which corporate governance enhances competitiveness primarily through its positive effect on productivity rather than through a direct pathway. Strengthening governance structures to improve decision-making and resource utilization may therefore be an effective strategy for increasing productivity and, ultimately, competitiveness in the pharmaceutical industry.

Indexed as

AlertnessCognitive FunctionCompetitive AdvantageErgonomicsIranian Pharmaceutical CompaniesMental WorkloadOrganizational PolicyPharmaceutical IndustryWork Schedule

Identifiers

PMID42871591
PMCPMC13659821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.